Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1494

1.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
[PubMed - indexed for MEDLINE]
2.

CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.

van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA.

Gynecol Oncol. 2010 Nov;119(2):265-9. doi: 10.1016/j.ygyno.2010.07.025. Epub 2010 Aug 24.

PMID:
20797777
[PubMed - indexed for MEDLINE]
3.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
[PubMed - indexed for MEDLINE]
4.

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.

Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I.

Gynecol Oncol. 2003 Sep;90(3):637-43. Erratum in: Gynecol Oncol. 2003 Dec;91(3):662.

PMID:
13678738
[PubMed - indexed for MEDLINE]
5.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr.

Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17.

PMID:
19447480
[PubMed - indexed for MEDLINE]
6.

Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.

Kang WD, Choi HS, Kim SM.

Gynecol Oncol. 2010 Jan;116(1):57-60. doi: 10.1016/j.ygyno.2009.09.019. Epub 2009 Oct 9.

PMID:
19818996
[PubMed - indexed for MEDLINE]
7.

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL.

Gynecol Oncol. 2009 Oct;115(1):81-5. doi: 10.1016/j.ygyno.2009.06.021. Epub 2009 Jul 12.

PMID:
19596139
[PubMed - indexed for MEDLINE]
8.

Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.

Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, Zorn KK, Krivak TC.

Int J Gynecol Cancer. 2010 Aug;20(6):932-5. doi: 10.1111/IGC.0b013e3181e37a54.

PMID:
20683398
[PubMed - indexed for MEDLINE]
9.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

PMID:
17999840
[PubMed - indexed for MEDLINE]
Free Article
10.

The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.

Le T, Hopkins L, Faught W, Fung-Kee-Fung M.

Gynecol Oncol. 2007 Jun;105(3):712-5. Epub 2007 Apr 2.

PMID:
17400284
[PubMed - indexed for MEDLINE]
11.

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.

Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP.

Clin Cancer Res. 2000 Aug;6(8):3260-70.

PMID:
10955812
[PubMed - indexed for MEDLINE]
Free Article
12.

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.

Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG.

J Clin Oncol. 1997 Apr;15(4):1309-17.

PMID:
9193322
[PubMed - indexed for MEDLINE]
Free Article
13.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
[PubMed - indexed for MEDLINE]
14.

Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.

Le T, Faught W, Hopkins L, Fung-Kee-Fung M.

J Obstet Gynaecol Can. 2008 Aug;30(8):665-70.

PMID:
18786288
[PubMed - indexed for MEDLINE]
15.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
[PubMed - indexed for MEDLINE]
16.

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.

Richardson DL, Seamon LG, Carlson MJ, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE.

Gynecol Oncol. 2008 Nov;111(2):233-6. doi: 10.1016/j.ygyno.2008.07.035. Epub 2008 Sep 2.

PMID:
18768214
[PubMed - indexed for MEDLINE]
17.

Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.

Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC.

Int J Gynecol Cancer. 2011 Aug;21(6):1013-7. doi: 10.1097/IGC.0b013e31821ce903.

PMID:
21792011
[PubMed - indexed for MEDLINE]
18.

[Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].

Zhao XD, Zhang Q, Zhang Y.

Ai Zheng. 2005 Aug;24(8):1002-5. Chinese.

PMID:
16086882
[PubMed - indexed for MEDLINE]
19.

A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer.

Steed H, Oza AM, Murphy J, Laframboise S, Lockwood G, DE Petrillo D, Sturgeon J, Rosen B.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:47-53.

PMID:
16515567
[PubMed - indexed for MEDLINE]
20.

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y.

J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1.

PMID:
18830625
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk